Demand for GLP-1 drugs is causing spending on traditional ... health plans struggling to contain already sky-high spending on prescription drugs. Spending growth for traditional drugs — simple ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

GLP-1 drugs, originally for type 2 diabetes, are increasingly used for weight loss, but they can worsen eating disorders. Rapid weight loss from these drugs can reinforce harmful eating behaviors ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...

A slow taper could work for them. For those without a ready supply, a short-term prescription for a brand-name GLP-1 might do the trick. Another option that shows potential is simply migrating ...

GLP-1s are driving traditional drug spending ... Seven key findings: 1. U.S. prescription drug spending hit $723 billion in 2023. Among commercial health plans, spending grew 8.9% in 2024, driven ...

Prescription weight loss medications, including GLP-1 agonists, orlistat, and Contrave, may be effective for some people. But other lifestyle changes are still necessary for long-term success.